Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sj ögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.

CONCLUSIONS: In the UKPSSR population, the use of ClinESSDAI instead of ESSDAI did not lead to significant changes in score distribution, potential eligibility or outcome measurement in trials, or in routine care when immunological tests are not available. These results need to be confirmed in other cohorts and with longitudinal data. PMID: 29442344 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29442344?dopt=Abstract

Source: Swiss Medical Weekly - February 14, 2018 Category: General Medicine Authors: Dumusc A, Ng WF, James K, Griffiths B, Price E, Pease C, Emery P, Lanyon P, Jones A, Bombardieri M, Sutcliffe N, Pitzalis C, Gupta M, McLaren J, Cooper A, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil Tags: Swiss Med Wkly Source Type: research

More News: Allergy & Immunology | Clinical Trials | General Medicine | Statistics | Switzerland Health